Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 8/20 | 0.45 |
| ▸ | MAOA | P21397 | 7/20 | 0.45 |
| ▸ | KDM1A | O60341 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24583885 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNA3CHRNA7MAOBMAOA | |
| SCHEMBL24584736 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNA3CHRNA7MAOBMAOA | |
| SCHEMBL24584739 | 1.00 | CHRNB2 (0.64) | CHRNB2CHRNA3CHRNA7MAOBMAOA | |
| Hydrochloric Acid SCHEMBL8040240 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA7MAOBMAOA | |
| Hydrochloric Acid SCHEMBL8040234 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA7MAOBMAOA | |
| SCHEMBL11780910 | 0.87 | CHRNB2 (0.49) | CHRNB2CHRNA3CHRNA7MAOBMAOA | |
| SCHEMBL19359148 | 0.81 | MAOB (0.46) | CHRNB2CHRNA3CHRNA7MAOBMAOA | |
| SCHEMBL10886603 | 0.80 | CHRNB2 (0.65) | CHRNB2CHRNA3CHRNA7TAAR1HTR2C | |
| SCHEMBL8313378 | 0.74 | MAOB (0.46) | MAOBMAOAKDM1ACYP2C19CYP2B6 | |
| SCHEMBL11789056 | 0.71 | MAOB (0.48) | MAOBMAOAKDM1ACYP2C19CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023308-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12023308-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11919836-B2 | Prodrugs of fencamfamine | Praxis Bioresearch, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2022140654-A1 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | THE BROAD INSTITUTE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11207278-B2 | Agents for reversing toxic proteinopathies | THE BROAD INSTITUTE, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210169827-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | THE BROAD INSTITUTE, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200399203-A1 | PRODRUGS OF FENCAMFAMINE | PRAXIS BIORESEARCH, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10662146-B2 | Prodrugs of fencamfamine | Praxis Bioresearch, LLC (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190023650-A1 | PRODRUGS OF FENCAMFAMINE | Praxis Bioresearch, LLC | 2019-01-24 | — | — | US | disclosed |
| US-6706747-B2 | TREATING ELEVATED INTRAOCULAR PRESSURE, DEPRESSION, NON INSULIN-DEPENDENT DIABETES, MALE IMPOTENCE AND OBESITY WHICH IS ALLEVIATED BY TREATMENT WITH AN ALPHA 2 BLOCKING AGENT | ALLERGAN, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030187047-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ALLERGAN SALES, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6569884-B2 | Trans-2-(3-phenyl-bicyclo(2.2.1)heptyl)-2-aminooxazoline, for example; treating intraocular pressure, noninsulin-dependent diabetes, male impotence and obesity | ALLERGAN | 2003-05-27 | — | — | US | disclosed |
| US-20020049241-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ALLERGAN SALES, INC. | 2002-04-25 | — | — | US | disclosed |
| EP-0770068-B1 | CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS ALPHA 2-ADRENERGIC BLOCKING AGENTS | ALLERGAN SALES INC (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6319935-B1 | USED IN TREATMENT OF ELEVATED INTRAOCULAR PRESSURE, NON INSULIN-DEPENDENT DIABETES, MALE IMPOTENCE AND OBESITY | ALLERGAN SALES, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6150389-A | ANTIDEPRESSANTS; TREATING ELEVATED INTRAOCULAR PRESSURE, E.G., GLAUCOMA; ANTIDIABETIC AGENTS FOR NON-INSULIN DEPENDENT DIABETES, SEXUAL DISORDERS, E.G., MALE IMPOTENCE AND OBESITY; E.G. TRANS-2-(3-PHENYL-BICYCLO(2.2.1)HEPTYL)-2-AMINOOXAZOLINE | ALLERGAN SALES, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-5731337-A | Conformationally rigid bicycle and adamantane derivatives useful as α2 | ALLERGAN (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0770068-A1 | CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS ALPHA 2-ADRENERGIC BLOCKING AGENTS | Allergan (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001813-A1 | CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS α2-ADRENERGIC BLOCKING AGENTS | ALLERGAN (US) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169827-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | CHRNB2 2960/4885CHRNA3 3657/4885CHRNA7 3439/4885 |
| US-20020049241-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ADRB2, ADRB1, ADRA1B | CHRNB2 45/4885CHRNA3 90/4885CHRNA7 61/4885 |
| US-11919836-B2 | Prodrugs of fencamfamine | FOLR2, FOLR1, CYP4F2 | CHRNB2 1221/4885CHRNA3 1098/4885CHRNA7 1114/4885 |
| US-11207278-B2 | Agents for reversing toxic proteinopathies | MUC1, TMIGD3, TMED9 | CHRNB2 2960/4885CHRNA3 3657/4885CHRNA7 3439/4885 |
| US-20030187047-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ADRB2, ADRB1, ADRA1B | CHRNB2 45/4885CHRNA3 90/4885CHRNA7 61/4885 |
| US-12023308-B2 | Agents for reversing toxic proteinopathies | MUC1, TMIGD3, TMED9 | CHRNB2 2960/4885CHRNA3 3657/4885CHRNA7 3439/4885 |
| US-20190023650-A1 | PRODRUGS OF FENCAMFAMINE | FOLR2, FOLR1, CYP4F2 | CHRNB2 1221/4885CHRNA3 1098/4885CHRNA7 1114/4885 |
| US-10662146-B2 | Prodrugs of fencamfamine | FEN1, PNMT, SLC19A1 | CHRNB2 520/4885CHRNA3 411/4885CHRNA7 410/4885 |
| US-20200399203-A1 | PRODRUGS OF FENCAMFAMINE | FOLR2, FOLR1, CYP4F2 | CHRNB2 1221/4885CHRNA3 1098/4885CHRNA7 1114/4885 |
| US-20220023233-A1 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | MUC1, TMIGD3, TMED9 | CHRNB2 2960/4885CHRNA3 3657/4885CHRNA7 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.